

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
00/000000	05/22/97	MILLER	F 00000/024000

KRISTINA BIEKER-BRADY
CLARK & EBLING, LLP
176 FEDERAL STREET
BOSTON MA 02110

HM11/0624

EXAMINER
TENG, S

ART. UNIT	PAPER NUMBER
1610	

06/24/99
DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Advisory Action	Application No. 08/920,272	Applicant(s) Miller et al.
	Examiner Sally Teng	Group Art Unit 1646

THE PERIOD FOR RESPONSE: [check only a) or b)]

- a) expires _____ months from the mailing date of the final rejection.
- b) expires either three months from the mailing date of the final rejection, or on the mailing date of this Advisory Action, whichever is later. In no event, however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

Appellant's Brief is due two months from the date of the Notice of Appeal filed on Apr 19, 1999 (or within any period for response set forth above, whichever is later). See 37 CFR 1.191(d) and 37 CFR 1.192(a).

Applicant's response to the final rejection, filed on Jun 7, 1999 has been considered with the following effect, but is NOT deemed to place the application in condition for allowance:

The proposed amendment(s):

- will be entered upon filing of a Notice of Appeal and an Appeal Brief.
- will not be entered because:
 - they raise new issues that would require further consideration and/or search. (See note below).
 - they raise the issue of new matter. (See note below).
 - they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
 - they present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: The term "postnatal mammal" is vague and indefinite. Does the term include adult mammals? "Multipotent precursor cells" is a limitation that has not been considered for 112, 1st and 2nd and prior art rejections.

Applicant's response has overcome the following rejection(s):

Newly proposed or amended claims _____ would be allowable if submitted in a separate, timely filed amendment cancelling the non-allowable claims.

The affidavit, exhibit or request for reconsideration has been considered but does NOT place the application in condition for allowance because:
for the reasons of record. Also, it is not clear that the isolated cells of Calof and Mayo are unipotent, as asserted by applicant..

The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.

For purposes of Appeal, the status of the claims is as follows (see attached written explanation, if any):

Claims allowed: None

Claims objected to: 28

Claims rejected: 1-11 and 21-30

The proposed drawing correction filed on _____ has has not been approved by the Examiner.

Note the attached Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Other Claims 8 and 10 are directed to cells differentiated from the cells of claim 1, but are not directed to isolated multipotent precursor cells. It is also pointed out that the claims are directed to products; thus, the source of their origin is immaterial to patentability.. Calof and Mayo discloses neurons which are cells differentiated from a multipotent precursor cell.


SALLY TENG
PRIMARY EXAMINER